| Disorder | Enzyme defect | Clinical Symptoms (if unmanaged) | Biochemical | Management |
|--|--|--|--|--|
| Tyrosinemia type I (HT-1) | Fumarylacetoacetate hydrolase (FAH) | Severe liver failure, vomiting, bleeding, neuropathy, neurological crises; cirrhosis; hepatocarcinoma | Turine and blood succinylacetone (diagnostic) TTYR; TMET (when liver disease has progressed) | Nitisinone (NTBC); PHE- and TYR- restricted diet (liver transplantation for select patients) |
| Tyrosinemia type II | Tyrosine aminotransferase (TAT) | Corneal lesions, hyperkeratosis Neurological complications | ↑ ↑ TYR (blood and urine), ↑ increased PHE, ↑ urinary phenolic acids, | PHE- and TYR- restricted diet |
| Tyrosinemia type III and neonatal tyrosinemia | 4-hydroxy phenylpyruvic acid dioxygenase (4-HPPD) | Impaired mental function Uncertain clinical relevance | ↑TYR; ↑ urinary 4-HPPA | PHE- and TYR- restricted diet; short term protein restriction in neonatal tyrosinemia |
| Hawkinsinuria | 4-hydroxyphenylpyruvic acid dioxygenase (4-HPPS); autosomal dominant mutation | Failure to thrive, acidosis; doubtful clinical relevance | Turinary hawkinsin acetic acid (2-L-cystein-S-yl, 4-dihydroxycyclohex-5-en-1-yl) | PHE- and TYR restricted diet + Vit.C supplementation in infancy |
| Alkaptonuria | Homogentisate oxygenase (HGD) | Arthritis, cardiac valve disease | 1 homogentisic acid | Low protein diet, possibly NTBC |